In its assessment in early 2022, the SCCS was unable to reach a conclusion on the safety of prostaglandin analogues substances. The industry has since provided new data, and the Scientific Committee has re-evaluated these substances and has just published the final version of its new Opinion.
Background
In the Opinion SCCS/1635/21, the SCCS was not able to conclude on the safety of “Isopropyl Cloprostenate” and “Ethyl Tafluprostamide” in cosmetic products in view of the limited data provided and the available information in published literature.
By January 2024, industry submitted additional evidence to support the safe use of “Ethyl Tafluprostamide” (DDDE), “Methylamido-Dihydro-Noralfaprostal” (MDN) and “Isopropyl Cloprostenate” (IPCP) in eyelash and eyebrow products.
The SCCS adopted its preliminary Opinion in May 2025.
For an exhaustive background information, see the articles
• Prostaglandin analogues: new request for Opinion to SCCS, CosmeticOBS, 9 April 2024
• Prostaglandin analogues: preliminary Opinion of the SCCS, CosmeticOBS, 10 June 2025
This Opinion has been subject to a commenting period of minimum eight weeks after its initial publication (from 6 June to 18 August due to holiday period).
Comments received during this period were considered by the SCCS.
Main changes occurred in all three preambles, 3.1.1.5 incl. SCCS comment, 3.1.5 incl. SCCS comment, 3.16 incl. SCCS comment, SCCS comment under 3.1.8, SCCS comment under 3.2.4, overall SCCS comment under 4.5.3.2, SCCS comment under 5.1.2.4 was deleted, SCCS comment under study 2 Applicant 2 of section 5.3.8, discussion 5.5, …
